Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
- Eisai President Naito Approves of Government Measures, Saying Japan’s Positioning “Improving Greatly”
March 2, 2012
- Pfizer Files Lawsuit Against Sandoz for Generic Lipitor, Sandoz to Contest Action
March 2, 2012
- Carna Biosciences Aiming to Out-License First Products to Megapharma in 2012 “if Possible”
March 2, 2012
- Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
- SBI to Enter Pharmaceutical Business Through Subsidiary, Considering Domestic Plant
March 1, 2012
- Takeda Initiates PIII Clinical Trials of Leuplin 6-Month Depot Formulation in Japan
March 1, 2012
- Takeda to Issue Straight Bonds for the First Time in 25 Years to Cover Nycomed Acquisition
March 1, 2012
- Takeda to Operate Global Vaccine Business, Aiming to Join Top 5 in 10 Years
March 1, 2012
- DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
- Nippon Kayaku Applies for Vascular Embolizing Agent NK939
March 1, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…